10 completed. 10 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 3 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow pibrentasvir: new trials by email Literature Review of pibrentasvir trials Research Report on pibrentasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of | Phase 1 / Phase 2 | Completed | University of California, San Diego | 12 | 2021-05-28 | 2022-05-24 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret Mavyret - Hepatitis C | Phase 2 | Completed | NYU Langone Health | 20 | 2018-05-12 | 2021-09-05 |
| A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 ABT-493, ABT-530 - Hepatitis C | Phase 2 / Phase 3 | Completed | AbbVie | 384 | 2015-06-22 | 2020-09-21 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus | Phase 2 / Phase 3 | Completed | AbbVie | 141 | 2015-04-01 | 2017-09-15 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection ABT-493, ABT-530, ribavirin (RBV) - Chronic Hepatitis C, Hepatitis C Virus | Phase 2 / Phase 3 | Completed | AbbVie | 694 | 2014-09-19 | 2021-07-30 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection ABT-493, ABT-530 - Chronic Hepatitis C, Hepatitis C Virus | Phase 2 | Completed | AbbVie | 174 | 2014-08-01 | 2021-07-13 |
| A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection ABT-450/ritonavir (r), ABT-530, Ribavirin (RBV) - Chronic Hepatitis C, Hepatitis C Virus | Phase 2 | Completed | AbbVie | 10 | 2014-04-01 | 2018-02-22 |
| A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) ABT-493, ABT-530, ABT-450/r/ABT-267, ABT-333 - Chronic Hepatitis C, Hepatitis C Virus | Phase 2 | Completed | AbbVie | 89 | 2013-11-01 | 2021-07-12 |
Hepatitis C (10) · Hepatitis C, Chronic (6) · Fibrosis (1) · Stress Disorders, Post-Traumatic (1)
AbbVie (6) · NYU Langone Health (1) · Ohio State University (1) · University of California, San Diego (1) · White River Junction Veterans Affairs Medical Center (1)
United States (5) · Australia (1) · Belgium (1) · Canada (1) · Germany (1) · New Zealand (1) · Puerto Rico (1) · United Kingdom (1)
Armen Asatryan, MD (2) · Bradley V Watts, MD, MPH (1) · Luis Angel, MD (1) · Reem Daloul, MD (1)
PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 26711747, PMID 26778412, PMID 27456384, PMID 28128852, PMID 28412293, PMID 28951228, PMID 30868245, PMID 35220658
2014 (2), 2015 (2)